Novonesis Launches Pet Business Unit: Global Biotech Giant Boosts Pet Health Sector

English Please Choose Your Language English Русский Español 日本語 Seeking excellence/solutions from China | ABOUT US | BLOG | CONTACT US All Product Name Product Keyword Product Model Product Summary Product Description Multi Field Search Home Services Products Pet Supplies About Us Blog Contact Us FAQ English Please Choose Your Language English Русский Español 日本語 All Product Name Product Keyword Product Model Product Summary Product Description Multi Field Search Home Services Products Pet Supplies About Us Blog Contact Us FAQ Seeking excellence/solutions from China | ABOUT US | BLOG | CONTACT US You are here: Home / Blog / Research on the pet industry / Novonesis Launches Pet Business Unit: Global Biotech Giant Boosts Pet Health Sector BLOG SEARCH Article title Article summary Article content Multi Field Search NEW PRODUCTS Image Product Name Automatic Smart Cat Litter Box 65L Extra Large Self-Cleaning Electric Cat Toilet, Fully Enclosed, Odor-Proof, Auto Scooping for Large Cats, Indoor Cats & Kittens Smart Automatic Cat Litter Box | Plasma Deodorization & Antibacterial Rechargeable Electric Pet Nail Grinder With LED Light Clipper Trimmer Polisher For Dogs Cats And Kittens All Products Novonesis Launches Pet Business Unit: Global Biotech Giant Boosts Pet Health Sector Views: 0 Author: Site Editor Publish Time: 2025-12-25 Origin: Site Inquire Biotechnology, a high-investment, long-cycle, and high-barrier track upstream of various industrial chains, is anchoring the promising new blue ocean of pet health with unprecedented determination and posture. In 2025, Novonesis, a global leader in the biotechnology field, officially announced the establishment of a Pet Business Unit under its Earth Health segment, marking its formal entry into the Chinese pet market. According to official sources, the business unit focuses on functional core raw materials for pets, with key emphasis on enzyme preparations and probiotic products, aiming to bring innovative biotech-based solutions to the global pet industry. A key question arises: when a global leading enterprise with a century of research experience turns its attention to the pet health track, what disruptive variables will it inject into the industry? And how will it redefine the future standards of pet nutrition and health? 01 Merger of Two Global Giants: Novonesis Starts a New Business Chapter Novonesis was formed by the merger of two long-established companies: Novozymes and Chr. Hansen. In December 2022, Novozymes, a global leader in industrial enzymes and microbial preparations, and Chr. Hansen, a top global probiotic company, reached a merger agreement. In January 2024, the proposed merger of the two companies was officially completed, announcing the formal establishment of Novonesis. The name "Novonesis" is derived from the Greek word "genesis," meaning "origin" or "beginning." It signifies the arrival of a new era of biological solutions, where biotech innovation will provide answers to a series of major challenges facing humanity. Its official Chinese name "诺和新元" (Nuòhé Xīnyuán) also embodies the same expectations, upholding the same philosophy while endowing it with connotations of traditional Chinese culture. Currently, Novonesis has two core business segments: the "Food & Health Biosolutions Segment," which focuses on biotech solutions for human health, food, and beverages; and the "Earth Health Biosolutions Segment," which is committed to biotech solutions for animal and plant health, home care, and various industrial applications. In 2025, Novonesis officially established the Pet Business Unit under the Earth Health segment, marking its formal entry into the Chinese pet market. Interestingly, Novozymes and Chr. Hansen—the two components of Novonesis—have previously developed pet-related products for the Chinese market as global leaders in enzymes and probiotics, providing strong support for the new business unit's expansion. "Bioenzymes and microbial technologies have high specificity, enabling precise and efficient solutions for specific pet health issues, thereby addressing the actual needs and pain points of pet owners," according to an official statement. By leveraging bioenzymes, functional proteins, and microorganisms, Novonesis' solutions not only meet pets' functional needs but are also greener, milder, safer, and more effective. For example, probiotics help maintain the balance of flora in animals, while bioenzyme solutions reduce the use of chemicals in production, making them more environmentally friendly. 02 Launch of Patented Keratinase and Probiotic Products in China: Biotech Solutions for Pet Hairball and Gut Health According to official information, Novonesis has currently launched two pet nutrition and health solutions in China: Targut™ Digest (Youchongxi®), a keratinase product targeting cats' hairball issues, and PET-PROESSENTIALS™ (Chongyixu®), an active probiotic product for pet gut health. Targut™ Digest (Youchongxi®) Developed based on Novonesis' innovative bioenzymatic hairball solution technology, this product's core advantage lies in using mild and safe bioenzyme proteins to actively break down hair in cats' bodies, allowing it to be easily excreted. It prevents hairball formation and ensures intestinal health. Meanwhile, this solution can be widely applied in hairball-relief health products and functional main foods, helping manufacturers build leading product strength. PET-PROESSENTIALS™ (Chongyixu®) A compound probiotic specially designed for dogs and cats, developed based on Chr. Hansen's patented probiotics. It uses a combination of three single strains of Bacillus subtilis, which can effectively improve pathogenic microorganisms common in pets' daily living environments, support the balance of pet intestinal flora, significantly enhance intestinal barrier function, and regulate immune capacity. It helps solve digestive discomfort and immune problems caused by microbial flora imbalance in dogs and cats of all ages, providing comprehensive protection. Additionally, the strains themselves have strong stability, ensuring that probiotic activity remains unchanged within 18 months of the pet food's shelf life. 03 Deepen Layout in Chinese Market: Focus on Localized Innovation and Production As a global leading biological solutions enterprise, Novonesis has established extensive industry recognition and brand reputation in the Chinese pet market with its profound accumulation in enzymes and probiotics. Since its establishment, the Pet Business Unit has relied on the group's technological and supply chain advantages to reach in-depth cooperation intentions with many well-known domestic pet brands and large production factories in just one year, continuously promoting the innovative application of biotechnology in pet nutrition and health. "In the next step, localized innovative R&D and production will also be a key focus of Novonesis' business development in the Chinese pet market," according to official sources. Novonesis currently has more than 40 R&D and application centers and over 20 production bases worldwide, building a global network consisting of R&D, application centers, and manufacturing bases. This enables it to transform cutting-edge R&D achievements into commercial products and promote them rapidly. Specifically in China, Novonesis has more than 1,000 employees. Its corporate headquarters and R&D center are located in Beijing, with a multi-purpose enzyme production pilot facility in Tianjin, a dedicated enzyme production base in Suzhou, a microbial production base in Shenyang, and sales and technical centers in Shanghai and Guangzhou. Relying on these three production bases, Novonesis has now realized the plan for most local production in China. At the same time, Novonesis is actively preparing for more capacity expansion and is expected to develop more production lines in the Chinese market. Looking to the future, Novonesis Pet Business Unit will continue to rely on its century-long technical accumulation in the microbial field, leverage its R&D layout and complete supply chain system in China, and continuously strengthen its presence in the Chinese pet market. It will actively cooperate with local partners, introduce more innovative technologies and functional raw materials, continuously expand the width and depth of its product line, and create sustainable solutions covering raw material processing and production, as well as improving pets' whole-life-cycle health. Currently, multiple new product R&D and market promotion plans of Novonesis have been included in the agenda and are steadily advancing . Novonesis pet business unit global pet health biotech market Novozymes Chr Hansen merger pet bioenzyme hairball solution Chinese pet health industry trends 2025 Related News Why Do 99% of Pet Owners Choose Pet Dryers? A $6.8 Billion Category That Most Pet Brands Are Still Sleeping On Your Cat Won't Tell You This, But Its Litter Box Is the Problem We have successfully designed and produced over 100 products, successfully entering high-end markets such as the United States, Japan, Germany, France, and Russia. INFORMATION Home Products About Us Blog Contact Us Sitemap Privacy Policy Video List CONTACT US  +86-755-28274716  +86-13662266273  sales@hanseektech.com  Room 1406H, Building C, Hengming Bay Chuanghui Center, Longcheng Street, Longgang District, Shenzhen, China Telephone +86-755-28274716 Cell phone +86-13662266273 Email sales@hanseektech.com Copyright © 2025 Hanseeker Innovation Co., Ltd. All Rights Reserved.